BRPI0413876A - tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos - Google Patents
tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicosInfo
- Publication number
- BRPI0413876A BRPI0413876A BRPI0413876-7A BRPI0413876A BRPI0413876A BR PI0413876 A BRPI0413876 A BR PI0413876A BR PI0413876 A BRPI0413876 A BR PI0413876A BR PI0413876 A BRPI0413876 A BR PI0413876A
- Authority
- BR
- Brazil
- Prior art keywords
- sup
- thienopyridin
- phenylacetamides
- derivatives useful
- antiangiogenic agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
"TIENOPIRIDIN-FENILACETAMIDAS E SEUS DERIVADOS úTEIS COMO AGENTES ANTIANGIOGêNICOS". A invenção está relacionada a compostos representados pela Fórmula (I): e com suas prodrogas, sais ou solvatos farmaceuticamente aceitáveis dos referidos compostos ou das referidas prodrogas, em que cada um de X¬ 1¬-X¬ 5¬ e R¬ 1¬-R¬ 5¬ são aqui definidos. A invenção está também relacionada com formulações farmacêuticas que contêm os compostos de Fórmula (I) e aos métodos de tratamento de distúrbios hiperproliferativos em mamífero mediante a administração de compostos de Fórmula (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49907703P | 2003-08-29 | 2003-08-29 | |
PCT/IB2004/002688 WO2005021554A1 (en) | 2003-08-29 | 2004-08-16 | Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0413876A true BRPI0413876A (pt) | 2006-10-24 |
Family
ID=34272772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0413876-7A BRPI0413876A (pt) | 2003-08-29 | 2004-08-16 | tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos |
Country Status (10)
Country | Link |
---|---|
US (1) | US7208500B2 (pt) |
EP (1) | EP1660504B1 (pt) |
JP (1) | JP2007504122A (pt) |
AT (1) | ATE412655T1 (pt) |
BR (1) | BRPI0413876A (pt) |
CA (1) | CA2536321A1 (pt) |
DE (1) | DE602004017479D1 (pt) |
ES (1) | ES2314444T3 (pt) |
MX (1) | MXPA06002296A (pt) |
WO (1) | WO2005021554A1 (pt) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101031570B (zh) | 2004-07-30 | 2012-09-05 | 梅特希尔基因公司 | Vegf受体和hgf受体信号的抑制剂 |
NZ554017A (en) | 2004-10-12 | 2010-06-25 | Astrazeneca Ab | [(Quinazolin-4-yloxy)phenyl]acetamide derivatives |
NZ563774A (en) | 2005-05-20 | 2010-04-30 | Methylgene Inc | Inhibitors of VEGF receptor and HGF receptor signaling |
US8093264B2 (en) * | 2005-05-20 | 2012-01-10 | Methylgene Inc. | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling |
WO2007035428A1 (en) * | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
TW200806675A (en) * | 2006-01-30 | 2008-02-01 | Array Biopharma Inc | Heterobicyclic thiophene compounds and methods of use |
UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
US20080064718A1 (en) * | 2006-03-22 | 2008-03-13 | Saavedra Oscar M | Inhibitors of protein tyrosine kinase activity |
US8008481B2 (en) | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
WO2007113548A1 (en) * | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives |
WO2007113565A1 (en) * | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives as anti-cancer agents |
US20090170131A1 (en) * | 2006-05-09 | 2009-07-02 | Juri Gelovani | Agents for Imaging Apoptosis |
US20110053931A1 (en) * | 2006-06-08 | 2011-03-03 | John Gaudino | Quinoline compounds and methods of use |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
US7960567B2 (en) * | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
BRPI0923670A2 (pt) | 2008-03-05 | 2013-07-30 | Methylgene Inc | inibidores da atividade de proteÍna tirosina quinase e seu uso, bem como composiÇço compreendendo os mesmos |
EP2340244A4 (en) | 2008-10-14 | 2012-07-25 | Ning Xi | COMPOUNDS AND APPLICATION PROCEDURES |
GB0901834D0 (en) | 2009-02-04 | 2009-03-11 | Syngenta Ltd | Novel herbicides |
GB0901835D0 (en) | 2009-02-04 | 2009-03-11 | Syngenta Ltd | Novel herbicides |
RU2011142597A (ru) * | 2009-03-21 | 2013-04-27 | Саншайн Лейк Фарма Ко., Лтд. | Производные сложных эфиров аминокислот, их соли и способы применения |
US8663210B2 (en) | 2009-05-13 | 2014-03-04 | Novian Health, Inc. | Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy |
JP2013503903A (ja) * | 2009-09-03 | 2013-02-04 | アラーガン インコーポレイテッド | チロシンキナーゼモジュレーターとしての化合物 |
US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
US20130096088A1 (en) * | 2011-09-30 | 2013-04-18 | Methylgene Inc. | Inhibitors of Protein Tyrosine Kinase Activity |
WO2013044360A1 (en) * | 2011-09-30 | 2013-04-04 | Methylgene Inc. | Inhibitors of protein tyrosine kinase activity |
WO2013044362A1 (en) * | 2011-09-30 | 2013-04-04 | Methylgene Inc. | Selected inhibitors of protein tyrosine kinase activity |
CN107683279B (zh) * | 2015-04-07 | 2020-11-03 | 广东众生睿创生物科技有限公司 | 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物 |
WO2018156946A1 (en) | 2017-02-24 | 2018-08-30 | Humanetics Corporation | Protecting tissue and mitigating injury from radiation-induced ionizing events |
US11129894B2 (en) | 2017-09-29 | 2021-09-28 | - Humanetics Corporation | Sensitizing cells to proton radiation |
CN111825605B (zh) * | 2019-04-19 | 2023-03-31 | 中国科学院上海药物研究所 | 芳基酮酰胺类化合物及其制备方法和用途 |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5587458A (en) * | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
DE69333807T2 (de) * | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
KR100225721B1 (ko) | 1994-02-23 | 1999-10-15 | 디. 제이. 우드, 스피겔 알렌 제이 | 4-헤테로사이클릴-치환된 퀴나졸린 유도체, 이들의 제조 방법 및항암제로서의 용도 |
WO1996014843A2 (en) | 1994-11-10 | 1996-05-23 | Cor Therapeutics, Inc. | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
CA2218503C (en) * | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
DE69531558T2 (de) | 1995-06-07 | 2004-03-18 | Pfizer Inc. | Heterocyclische kondensierte pyrimidin-derivate |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
DE69734149T2 (de) | 1996-03-15 | 2006-07-06 | Astrazeneca Ab | Cinoline derivate und verwendung als heilmittel |
BR9709959A (pt) | 1996-06-24 | 2000-05-09 | Pfizer | Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas |
AU2710597A (en) * | 1996-06-27 | 1998-01-14 | Pfizer Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors |
BR9710362A (pt) | 1996-07-13 | 1999-08-17 | Glaxo Group Ltd | Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto |
DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
DE69712496T2 (de) | 1996-07-18 | 2002-08-29 | Pfizer | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
KR20000068248A (ko) | 1996-08-23 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐아미노 하이드록삼산 유도체 |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
US6548524B2 (en) * | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
JP2000505109A (ja) | 1996-11-27 | 2000-04-25 | ファイザー・インク | 縮合二環式ピリミジン誘導体 |
PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
US6303636B1 (en) | 1997-02-03 | 2001-10-16 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
WO1998051344A1 (en) | 1997-05-12 | 1998-11-19 | The Kennedy Institute Of Rheumatology | Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy |
EP0984692A4 (en) | 1997-05-30 | 2001-02-21 | Merck & Co Inc | ANGIOGENESIS INHIBITORS |
DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
JP2001518470A (ja) | 1997-09-26 | 2001-10-16 | メルク エンド カムパニー インコーポレーテッド | 新規な血管形成阻害剤 |
GB9722320D0 (en) * | 1997-10-22 | 1997-12-17 | Janssen Pharmaceutica Nv | Human cell cycle checkpoint proteins |
JP2001522853A (ja) | 1997-11-11 | 2001-11-20 | ファイザー・プロダクツ・インク | 抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体 |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
AU2825899A (en) * | 1998-03-12 | 1999-09-27 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
AU3850299A (en) | 1998-05-20 | 1999-12-06 | Kyowa Hakko Kogyo Co. Ltd. | Vegf activity inhibitors |
WO1999061422A1 (en) | 1998-05-29 | 1999-12-02 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
AU4393199A (en) * | 1998-06-26 | 2000-01-17 | Takeda Chemical Industries Ltd. | Thienopyridine compounds, their production and use |
US6383744B1 (en) * | 1998-07-10 | 2002-05-07 | Incyte Genomics, Inc. | Human checkpoint kinase |
EP1135135A4 (en) | 1998-09-18 | 2006-08-09 | Smithkline Beecham Corp | CHK1 KINASE INHIBITORS |
US6649645B1 (en) | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
CA2356748A1 (en) | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia |
TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
JP4652648B2 (ja) | 1999-08-27 | 2011-03-16 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | キメラアンチセンスオリゴヌクレオチド、およびその細胞トランスフェクション処方物 |
DK1218494T3 (da) | 1999-09-22 | 2005-08-08 | Canbas Co Ltd | Præparater og fremgangsmåder til inhibering af C2-cellecyklusstandsning og sensibilisering af celler til DNA-beskadigende midler |
US6211164B1 (en) * | 2000-03-10 | 2001-04-03 | Abbott Laboratories | Antisense oligonucleotides of the human chk1 gene and uses thereof |
EP1265635A1 (en) | 2000-03-22 | 2002-12-18 | Glaxo Group Limited | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
CZ20023518A3 (cs) | 2000-03-31 | 2004-04-14 | Imclone Systems Incorporated | Léčivo pro inhibici růstu buněk non-solidních nádorů |
GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
DE60118186T2 (de) | 2000-05-12 | 2006-12-28 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem) |
WO2002030453A1 (en) | 2000-10-12 | 2002-04-18 | Beth Israel Deaconess Medical Center, Inc. | Methods of inhibiting angiogenesis using nadph oxidase inhibitors |
AU2002223684A1 (en) | 2000-11-22 | 2002-06-03 | Novartis Pharma Gmbh | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
WO2002064170A1 (en) | 2001-02-09 | 2002-08-22 | Children's Medical Center Corporation | A method for treating cancer and increasing hematocrit levels |
UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
AU2002345792A1 (en) * | 2001-06-21 | 2003-01-08 | Pfizer Inc. | Thienopyridine and thienopyrimidine anticancer agents |
EP1416960A4 (en) | 2001-07-13 | 2006-02-22 | Imclone Systems Inc | VEGFR-1 ANTIBODY FOR THE TREATMENT OF BREAST CANCER |
WO2003009852A1 (en) * | 2001-07-24 | 2003-02-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
NZ532418A (en) | 2001-10-25 | 2007-02-23 | Novartis Ag | Combinations comprising a selective cyclooxygenase-2 inhibitor and a microtubule interfering agent |
-
2004
- 2004-08-16 MX MXPA06002296A patent/MXPA06002296A/es unknown
- 2004-08-16 AT AT04769139T patent/ATE412655T1/de not_active IP Right Cessation
- 2004-08-16 JP JP2006524445A patent/JP2007504122A/ja not_active Withdrawn
- 2004-08-16 ES ES04769139T patent/ES2314444T3/es active Active
- 2004-08-16 EP EP04769139A patent/EP1660504B1/en not_active Not-in-force
- 2004-08-16 CA CA002536321A patent/CA2536321A1/en not_active Abandoned
- 2004-08-16 DE DE602004017479T patent/DE602004017479D1/de active Active
- 2004-08-16 WO PCT/IB2004/002688 patent/WO2005021554A1/en active Application Filing
- 2004-08-16 BR BRPI0413876-7A patent/BRPI0413876A/pt not_active IP Right Cessation
- 2004-08-26 US US10/928,674 patent/US7208500B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE412655T1 (de) | 2008-11-15 |
MXPA06002296A (es) | 2006-05-22 |
US7208500B2 (en) | 2007-04-24 |
JP2007504122A (ja) | 2007-03-01 |
WO2005021554A1 (en) | 2005-03-10 |
US20050090509A1 (en) | 2005-04-28 |
ES2314444T3 (es) | 2009-03-16 |
EP1660504B1 (en) | 2008-10-29 |
DE602004017479D1 (de) | 2008-12-11 |
EP1660504A1 (en) | 2006-05-31 |
CA2536321A1 (en) | 2005-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0413876A (pt) | tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos | |
GT199900139A (es) | Derivados de quinolin-2-ona ùtiles como agentes contra el càncer. | |
MY139357A (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
TR200102136T2 (tr) | Antikanser maddeleri olarak faydaı ikame-edilmiş bisiklik türevler. | |
TR200003478T2 (tr) | Antikanser maddeleri olarak faydalı izotiyazol türevleri | |
EA200600892A1 (ru) | Новые хинолиновые производные | |
EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
PT1029853E (pt) | Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos | |
BG105365A (en) | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | |
NO20085060L (no) | Triazolpyrazinderivater anvendelige som anti-cancermidler | |
CY1106674T1 (el) | Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους | |
AR029634A1 (es) | Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento | |
AP1895A (en) | Novel benzoimidazole derivatives useful as antiproliferative agents. | |
MXPA05006420A (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal. | |
YU95102A (sh) | Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija | |
RS20050469A (en) | Pyrrolopyrimidine derivatives | |
SG159388A1 (en) | Antibacterial agents | |
GEP20094736B (en) | Prodrugs of piperazine and substituted piperidine antiviral agents | |
BR9805734A (pt) | Derivados de imidazolin-4-ona úteis como agentes anticancerìgenos. | |
DK1697371T3 (da) | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer | |
BRPI0414011A (pt) | naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos | |
WO2003074529A3 (en) | iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS | |
ATE330956T1 (de) | Bizyklisch substituierte 4- aminopyridopyrimidinderivate | |
ECSP992984A (es) | Derivados de isotiazol utiles como agentes anticancerosos | |
DOP2003000595A (es) | Indolil-urea derivado de tienopiridinas utiles como agentes antiangionicos,y procedimientos para su uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |